Synergistic Effects and Mechanisms of Budesonide in Combination with Fluconazole Against Resistant Candida Albicans

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Dec 23

PMID 28006028

Citations 11

Authors

Xiuyun Li

Cuixiang Yu

Xin Huang

Shujuan Sun

Affiliations

Soon will be listed here.

Abstract

Candida albicans is an important opportunistic pathogen, causing both superficial mucosal infections and life-threatening systemic diseases in the clinic. The emergence of drug resistance in Candida albicans has become a noteworthy phenomenon due to the extensive use of antifungal agents and the development of biofilms. This study showed that budesonide potentiates the antifungal effect of fluconazole against fluconazole-resistant Candida albicans strains both in vitro and in vivo. In addition, our results demonstrated, for the first time, that the combination of fluconazole and budesonide can reverse the resistance of Candida albicans by inhibiting the function of drug transporters, reducing the formation of biofilms, promoting apoptosis and inhibiting the activity of extracellular phospholipases. This is the first study implicating the effects and mechanisms of budesonide against Candida albicans alone or in combination with fluconazole, which may ultimately lead to the identification of new potential antifungal targets.

Citing Articles

Preparation and analysis of quinoa active protein (QAP) and its mechanism of inhibiting from a transcriptome perspective.

Zhang X, Zheng C, Ge W, Li X, Wang X, Sun Y PeerJ. 2025; 13:e18961.

PMID: 39963196 PMC: 11831975. DOI: 10.7717/peerj.18961.

Screening antibiofilm activity of invasive plants growing at the Slope Merapi Mountain, Central Java, against Candida albicans.

Desrini S, Girardot M, Imbert C, Mustofa M, Nuryastuti T BMC Complement Med Ther. 2023; 23(1):232.

PMID: 37438777 PMC: 10339508. DOI: 10.1186/s12906-023-04044-2.

Synergy and Mechanism of Leflunomide Plus Fluconazole Against Resistant : An in vitro Study.

Li X, Zhang N, Zhang L, Liu C, Zheng S, Lou H Infect Drug Resist. 2023; 16:4147-4158.

PMID: 37396066 PMC: 10314782. DOI: 10.2147/IDR.S415229.

Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.

Kane A, Carter D Pharmaceuticals (Basel). 2022; 15(4).

PMID: 35455479 PMC: 9027798. DOI: 10.3390/ph15040482.

Antifungal Effects and Potential Mechanisms of Benserazide Hydrochloride Alone and in Combination with Fluconazole Against .

Chen X, Wu J, Sun L, Nie J, Su S, Sun S Drug Des Devel Ther. 2021; 15:4701-4711.

PMID: 34815665 PMC: 8605804. DOI: 10.2147/DDDT.S336667.

References

Wang T, Shi G, Shao J, Wu D, Yan Y, Zhang M . In vitro antifungal activity of baicalin against Candida albicans biofilms via apoptotic induction. Microb Pathog. 2015; 87:21-9. DOI: 10.1016/j.micpath.2015.07.006. View

Sardi J, de Souza Pitangui N, Rodriguez-Arellanes G, Taylor M, Fusco-Almeida A, Mendes-Giannini M . Highlights in pathogenic fungal biofilms. Rev Iberoam Micol. 2013; 31(1):22-9. DOI: 10.1016/j.riam.2013.09.014. View

Gourlay C, Du W, Ayscough K . Apoptosis in yeast--mechanisms and benefits to a unicellular organism. Mol Microbiol. 2006; 62(6):1515-21. DOI: 10.1111/j.1365-2958.2006.05486.x. View

Polak A . Virulence of Candida albicans mutants. Mycoses. 1992; 35(1-2):9-16. DOI: 10.1111/j.1439-0507.1992.tb00813.x. View

Mathe L, Van Dijck P . Recent insights into Candida albicans biofilm resistance mechanisms. Curr Genet. 2013; 59(4):251-64. PMC: 3824241. DOI: 10.1007/s00294-013-0400-3. View

Cannon R, Lamping E, Holmes A, Niimi K, Tanabe K, Niimi M . Candida albicans drug resistance another way to cope with stress. Microbiology (Reading). 2007; 153(Pt 10):3211-3217. DOI: 10.1099/mic.0.2007/010405-0. View

Gu W, Guo D, Zhang L, Xu D, Sun S . The Synergistic Effect of Azoles and Fluoxetine against Resistant Candida albicans Strains Is Attributed to Attenuating Fungal Virulence. Antimicrob Agents Chemother. 2016; 60(10):6179-88. PMC: 5038273. DOI: 10.1128/AAC.03046-15. View

Price M, Wilkinson I, Gentry L . Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia. 1982; 20(1):7-14. DOI: 10.1080/00362178285380031. View

Li R, Kumar R, Tati S, Puri S, Edgerton M . Candida albicans flu1-mediated efflux of salivary histatin 5 reduces its cytosolic concentration and fungicidal activity. Antimicrob Agents Chemother. 2013; 57(4):1832-9. PMC: 3623299. DOI: 10.1128/AAC.02295-12. View

10.

Zhang L, Keogh S, Rickard C . Reducing the risk of infection associated with vascular access devices through nanotechnology: a perspective. Int J Nanomedicine. 2013; 8:4453-66. PMC: 3839805. DOI: 10.2147/IJN.S50312. View

11.

Epp E, Vanier G, Harcus D, Lee A, Jansen G, Hallett M . Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence. PLoS Pathog. 2010; 6(2):e1000753. PMC: 2816695. DOI: 10.1371/journal.ppat.1000753. View

12.

Youngsaye W, Hartland C, Morgan B, Ting A, Nag P, Vincent B . ML212: A small-molecule probe for investigating fluconazole resistance mechanisms in Candida albicans. Beilstein J Org Chem. 2013; 9:1501-7. PMC: 3740683. DOI: 10.3762/bjoc.9.171. View

13.

Liu S, Yue L, Gu W, Li X, Zhang L, Sun S . Synergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicans. PLoS One. 2016; 11(3):e0150859. PMC: 4795682. DOI: 10.1371/journal.pone.0150859. View

14.

Jones W, Chastain C, Wright P . Iatrogenic cushing syndrome secondary to a probable interaction between voriconazole and budesonide. Pharmacotherapy. 2014; 34(7):e116-9. DOI: 10.1002/phar.1432. View

15.

Golabek K, Strzelczyk J, Owczarek A, Cuber P, Slemp-Migiel A, Wiczkowski A . Selected mechanisms of molecular resistance of Candida albicans to azole drugs. Acta Biochim Pol. 2015; 62(2):247-51. DOI: 10.18388/abp.2014_940. View

16.

Sarkar S, Uppuluri P, Pierce C, Lopez-Ribot J . In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms. Antimicrob Agents Chemother. 2013; 58(2):1183-6. PMC: 3910858. DOI: 10.1128/AAC.01745-13. View

17.

Calabrese D, Bille J, Sanglard D . A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology (Reading). 2000; 146 ( Pt 11):2743-2754. DOI: 10.1099/00221287-146-11-2743. View

18.

Fiori A, Van Dijck P . Potent synergistic effect of doxycycline with fluconazole against Candida albicans is mediated by interference with iron homeostasis. Antimicrob Agents Chemother. 2012; 56(7):3785-96. PMC: 3393430. DOI: 10.1128/AAC.06017-11. View

19.

Bink A, Govaert G, Vandenbosch D, Kucharikova S, Coenye T, Nelis H . Transcription factor Efg1 contributes to the tolerance of Candida albicans biofilms against antifungal agents in vitro and in vivo. J Med Microbiol. 2012; 61(Pt 6):813-819. DOI: 10.1099/jmm.0.041020-0. View

20.

Fukushima C, Matsuse H, Tomari S, Obase Y, Miyazaki Y, Shimoda T . Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann Allergy Asthma Immunol. 2003; 90(6):646-51. DOI: 10.1016/S1081-1206(10)61870-4. View